American Bio Medica Corporation (ABMC)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -1.16 Million USD | -167.97% |
| 2021 | -199 Thousand USD | 30.11% |
| 2020 | -540 Thousand USD | -4.72% |
| 2019 | -340 Thousand USD | 22.18% |
| 2018 | -661 Thousand USD | -294.82% |
| 2017 | -193 Thousand USD | -16.27% |
| 2016 | 34 Thousand USD | -22.06% |
| 2015 | 180 Thousand USD | -28.3% |
| 2014 | -133 Thousand USD | 89.54% |
| 2013 | -360 Thousand USD | -25.84% |
| 2012 | -796 Thousand USD | -714.5% |
| 2011 | 140 Thousand USD | 153.69% |
| 2010 | -241 Thousand USD | 27.16% |
| 2009 | -360 Thousand USD | -24.07% |
| 2008 | -283 Thousand USD | 36.92% |
| 2007 | -401 Thousand USD | -169.37% |
| 2006 | 627 Thousand USD | 2582.61% |
| 2005 | 38 Thousand USD | -96.17% |
| 2004 | 615 Thousand USD | -29.21% |
| 2003 | 1.04 Million USD | -9.39% |
| 2002 | 903 Thousand USD | 0.0% |
| 2001 | - USD | 100.0% |
| 2000 | -1.97 Million USD | -17.55% |
| 1999 | -1.97 Million USD | 65.04% |
| 1998 | -1.6 Million USD | -526.42% |
| 1997 | -4.4 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q2 | - USD | 100.0% |
| 2023 Q1 | -1.12 Million USD | -327.76% |
| 2023 Q3 | - USD | 0.0% |
| 2022 Q2 | -333 Thousand USD | -4.72% |
| 2022 Q1 | -318 Thousand USD | -97.52% |
| 2022 FY | - USD | -167.97% |
| 2022 Q4 | -263 Thousand USD | -5.62% |
| 2022 Q3 | -249 Thousand USD | 25.23% |
| 2021 Q4 | -161 Thousand USD | -140.86% |
| 2021 FY | - USD | 30.11% |
| 2021 Q1 | -491 Thousand USD | -154.4% |
| 2021 Q2 | -176 Thousand USD | 64.15% |
| 2021 Q3 | 394 Thousand USD | 323.86% |
| 2020 FY | - USD | -4.72% |
| 2020 Q2 | 37 Thousand USD | 114.68% |
| 2020 Q3 | -153 Thousand USD | -513.51% |
| 2020 Q1 | -252 Thousand USD | -37.7% |
| 2020 Q4 | -193 Thousand USD | -26.14% |
| 2019 Q1 | -174 Thousand USD | 50.0% |
| 2019 Q2 | 35 Thousand USD | 120.11% |
| 2019 Q3 | -59 Thousand USD | -268.57% |
| 2019 Q4 | -183 Thousand USD | -210.17% |
| 2019 FY | - USD | 22.18% |
| 2018 FY | - USD | -294.82% |
| 2018 Q4 | -348 Thousand USD | -210.71% |
| 2018 Q3 | -112 Thousand USD | -138.3% |
| 2018 Q1 | -176 Thousand USD | 15.38% |
| 2018 Q2 | -47 Thousand USD | 73.3% |
| 2017 Q1 | -45 Thousand USD | 54.55% |
| 2017 Q3 | 26 Thousand USD | 30.0% |
| 2017 Q4 | -208 Thousand USD | -900.0% |
| 2017 FY | - USD | -16.27% |
| 2017 Q2 | 20 Thousand USD | 144.44% |
| 2016 Q4 | -99 Thousand USD | -167.57% |
| 2016 FY | - USD | -22.06% |
| 2016 Q1 | -68 Thousand USD | 59.04% |
| 2016 Q2 | 37 Thousand USD | 154.41% |
| 2016 Q3 | -37 Thousand USD | -200.0% |
| 2015 Q4 | -166 Thousand USD | -344.12% |
| 2015 Q2 | -11 Thousand USD | 59.26% |
| 2015 Q3 | 68 Thousand USD | 718.18% |
| 2015 FY | - USD | -28.3% |
| 2015 Q1 | -27 Thousand USD | 82.24% |
| 2014 FY | - USD | 89.54% |
| 2014 Q1 | 90 Thousand USD | 137.5% |
| 2014 Q2 | 53 Thousand USD | -41.11% |
| 2014 Q4 | -152 Thousand USD | -55.1% |
| 2014 Q3 | -98 Thousand USD | -284.91% |
| 2013 Q3 | -258 Thousand USD | -42.54% |
| 2013 Q4 | -240 Thousand USD | 6.98% |
| 2013 FY | - USD | -25.84% |
| 2013 Q2 | -181 Thousand USD | 45.32% |
| 2013 Q1 | -331 Thousand USD | 30.61% |
| 2012 Q4 | -477 Thousand USD | -143.37% |
| 2012 Q3 | -196 Thousand USD | -9900.0% |
| 2012 Q2 | 2000.00 USD | 101.48% |
| 2012 Q1 | -135 Thousand USD | -240.63% |
| 2012 FY | - USD | -714.5% |
| 2011 Q1 | -305 Thousand USD | -38.64% |
| 2011 FY | - USD | 153.69% |
| 2011 Q3 | 97 Thousand USD | -60.08% |
| 2011 Q4 | 96 Thousand USD | -1.03% |
| 2011 Q2 | 243 Thousand USD | 179.67% |
| 2010 Q2 | 294 Thousand USD | 305.59% |
| 2010 FY | - USD | 27.16% |
| 2010 Q4 | -220 Thousand USD | -25.71% |
| 2010 Q3 | -175 Thousand USD | -159.52% |
| 2010 Q1 | -143 Thousand USD | -160.0% |
| 2009 Q3 | -100 Thousand USD | -17.65% |
| 2009 FY | - USD | -24.07% |
| 2009 Q1 | -119 Thousand USD | 75.1% |
| 2009 Q2 | -85 Thousand USD | 28.57% |
| 2009 Q4 | -55 Thousand USD | 45.0% |
| 2008 Q1 | -66 Thousand USD | -162.26% |
| 2008 FY | - USD | 36.92% |
| 2008 Q2 | 55 Thousand USD | 183.33% |
| 2008 Q4 | -478 Thousand USD | -318.26% |
| 2008 Q3 | 219 Thousand USD | 298.18% |
| 2007 Q3 | -107 Thousand USD | 59.0% |
| 2007 Q4 | 106 Thousand USD | 199.07% |
| 2007 FY | - USD | -169.37% |
| 2007 Q1 | -157 Thousand USD | -176.96% |
| 2007 Q2 | -261 Thousand USD | -66.24% |
| 2006 FY | - USD | 2582.61% |
| 2006 Q1 | 127 Thousand USD | 115.62% |
| 2006 Q2 | 209 Thousand USD | 64.57% |
| 2006 Q3 | 87 Thousand USD | -58.37% |
| 2006 Q4 | 204 Thousand USD | 134.48% |
| 2005 Q3 | 408 Thousand USD | 53.38% |
| 2005 Q4 | -813 Thousand USD | -299.26% |
| 2005 Q2 | 266 Thousand USD | 83.45% |
| 2005 Q1 | 145 Thousand USD | 2316.67% |
| 2005 FY | - USD | -96.17% |
| 2004 Q1 | 323 Thousand USD | 162.6% |
| 2004 Q4 | 6000.00 USD | -98.44% |
| 2004 Q2 | 123 Thousand USD | -61.92% |
| 2004 Q3 | 385 Thousand USD | 213.01% |
| 2004 FY | - USD | -29.21% |
| 2003 Q2 | 313 Thousand USD | 447.83% |
| 2003 Q1 | 39 Thousand USD | -75.53% |
| 2003 Q4 | 123 Thousand USD | -78.68% |
| 2003 Q3 | 577 Thousand USD | 357.94% |
| 2003 FY | - USD | -9.39% |
| 2002 FY | - USD | 0.0% |
| 2002 Q1 | 64 Thousand USD | 0.0% |
| 2002 Q2 | 268 Thousand USD | 624.32% |
| 2002 Q3 | 477 Thousand USD | 77.61% |
| 2002 Q4 | 94 Thousand USD | -80.25% |
| 2001 FY | - USD | 100.0% |
| 2001 Q3 | -812 Thousand USD | -1324.56% |
| 2001 Q2 | -62 Thousand USD | 93.6% |
| 2001 Q1 | -891 Thousand USD | -112.14% |
| 2000 Q2 | -97 Thousand USD | 92.69% |
| 2000 FY | - USD | -17.55% |
| 2000 Q3 | -405 Thousand USD | -317.53% |
| 2000 Q1 | -1.5 Million USD | -242.01% |
| 2000 Q4 | -420 Thousand USD | -3.7% |
| 1999 Q2 | -82 Thousand USD | 83.01% |
| 1999 Q3 | -5000.00 USD | 104.29% |
| 1999 FY | - USD | 65.04% |
| 1999 Q4 | -384 Thousand USD | -6566.67% |
| 1999 Q1 | -824 Thousand USD | -43.55% |
| 1998 Q3 | - USD | 116.03% |
| 1998 Q4 | -700 Thousand USD | -1347.83% |
| 1998 FY | - USD | -526.42% |
| 1998 Q1 | -3.7 Million USD | -516.67% |
| 1998 Q2 | -287 Thousand USD | 92.24% |
| 1997 Q4 | -700 Thousand USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Arrayit Corporation | -3.07 Million USD | 62.21% |
| Atlantic International Corp. | -5.38 Million USD | 78.421% |
| Biocept, Inc. | -30.24 Million USD | 96.154% |
| Bioqual, Inc. | 3.03 Million USD | 138.354% |
| CardioGenics Holdings Inc | -757.37 Thousand USD | -53.557% |
| DermTech, Inc. | -97.89 Million USD | 98.812% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.91 Billion USD | 100.04% |
| HTG Molecular Diagnostics, Inc. | -20.24 Million USD | 94.255% |
| iMD Companies, Inc. | -154.65 Thousand USD | -651.977% |
| IDenta Corp. | 71.58 Thousand USD | 1724.597% |
| Interpace Biosciences, Inc. | 3.83 Million USD | 130.31% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | 3105.945% |
| InVitro International | 6680.00 USD | 17510.18% |
| Lumos Diagnostics Holdings Limited | -5.43 Million USD | 78.606% |
| Many Bright Ideas Technologies Inc. | -12.13 Thousand USD | -9484.638% |
| Medical Imaging Corp. | -896.74 Thousand USD | -29.692% |
| NovelStem International Corp. | -3.78 Million USD | 69.28% |
| Optigenex Inc. | -1.18 Million USD | 1.999% |
| PharmChem, Inc. | 1.05 Million USD | 210.361% |
| Proteome Sciences plc | -1.13 Million USD | -2.287% |
| Response Genetics, Inc | -19.66 Million USD | 94.086% |
| Rennova Health, Inc. | -234.81 Thousand USD | -395.284% |
| RushNet, Inc. | -614.85 Thousand USD | -89.151% |
| ScreenPro Security Inc. | -3.43 Million USD | 66.142% |
| Stella Diagnostics Inc. | -5.7 Million USD | 79.623% |
| StageZero Life Sciences Ltd. | -10.27 Million USD | 88.676% |
| Todos Medical Ltd. | -9.39 Million USD | 87.62% |